SCHEMBL12050010

SCHEMBL12050010

CCC(=O)c1cccc2cc(C)ccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.50
PTPN1 P18031 2/20 0.45
KMT2A Q03164 6/20 0.43
MEN1 O00255 5/20 0.43
POLB P06746 3/20 0.43
ALDH1A1 P00352 3/20 0.43
MAPT P10636 3/20 0.43
HPGD P15428 3/20 0.43
TDP1 Q9NUW8 3/20 0.43
KDM4E B2RXH2 2/20 0.43
GMNN O75496 2/20 0.43
LMNA P02545 2/20 0.43
MAPK1 P28482 2/20 0.43
BLM P54132 2/20 0.43
PMP22 Q01453 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
CMKLR1 Q99788 2/20 0.43
TP53 P04637 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31231224 1.00 CYP1A2 (0.50) CYP1A2PTPN1KMT2AMEN1POLB
SCHEMBL10953917 0.83 KMT2A (0.58) CYP1A2PTPN1KMT2AMEN1POLB
SCHEMBL27206810 0.82 CYP1A2 (0.57) CYP1A2PTPN1KMT2APOLBTDP1
SCHEMBL31475700 0.82 CYP1A2 (0.57) CYP1A2PTPN1KMT2APOLBTDP1
SCHEMBL4097322 0.82 CNR2 (0.44) CYP1A2PTPN1KMT2AMEN1POLB
SCHEMBL4096984 0.82 PTPN1 (0.44) CYP1A2PTPN1KMT2AMEN1POLB
SCHEMBL29254661 0.81 CYP1A2 (0.48) CYP1A2PTPN1KMT2AMEN1POLB
SCHEMBL344157 0.81 PTPN1 (0.66) CYP1A2PTPN1KMT2AMEN1POLB
SCHEMBL31522164 0.81 PTPN1 (0.66) CYP1A2PTPN1KMT2AMEN1POLB
SCHEMBL9857199 0.81 CYP1A2 (0.55) CYP1A2PTPN1KMT2APOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118307394-A Purification method of crude product of 2-methyl-6-propionylnaphthalene 品恩赢创(苏州)新材料科技有限公司 2024-07-09 CN disclosed
US-20140031334-A1 DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-01-30 US disclosed
CN-102026988-B 3-substituted propanamines SK HOLDINGS CO LTD 2013-07-03 CN disclosed
US-8071600-B2 Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-12-06 US disclosed
CN-102026988-A 3-substituted propanamines SK HOLDINGS CO LTD 2011-04-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031334-A1 DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS GRIN2C, GRIN2B, PMP22 CYP1A2 103/4885PTPN1 1331/4885KMT2A 480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.